Clinical Outcomes of Drug-Eluting Bead Transarterial Chemoembolization Loaded with Raltitrexed for the Treatment of Unresectable or Recurrent Hepatocellular Carcinoma
Objectives. Although raltitrexed shows therapeutic effects in many types of malignant tumors, the therapeutic effects and safety of drug-eluting bead transarterial chemoembolization (DEB-TACE) loaded with raltitrexed for the treatment of hepatocellular carcinoma (HCC) are rare. This study aimed to i...
Saved in:
Main Authors: | Yonghua Bi, Dechao Jiao, Jianzhuang Ren, Xinwei Han |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-01-01
|
Series: | Canadian Journal of Gastroenterology and Hepatology |
Online Access: | http://dx.doi.org/10.1155/2022/2602121 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A Lethal Complication after Transarterial Chemoembolization with Drug-Eluting Beads for Hepatocellular Carcinoma
by: Adriana Toro, et al.
Published: (2015-01-01) -
Conventional and drug‑eluting bead transarterial chemoembolization in patients with inoperable intrahepatic cholangiocarcinoma: a meta‑analysis
by: Su-Rong Pan, et al.
Published: (2024-11-01) -
TRACE Model: Predicting Treatment Response to Transarterial Chemoembolization in Unresectable Hepatocellular Carcinoma
by: Wang W, et al.
Published: (2025-01-01) -
Idarubicin-loaded drug-eluting microspheres transarterial chemoembolization for intermediate stage hepatocellular carcinoma: safety, efficacy, and pharmacokinetics
by: Korsic Spela, et al.
Published: (2024-10-01) -
Transarterial radioembolization versus chemoembolization for hepatocellular carcinoma: a meta-analysis
by: Wenxiao Lu, et al.
Published: (2025-01-01)